|
Clinical Trials for Hemangiosarcoma |
|
|
|
CCB02. The National Cancer Institute and UCDAVIS
Eligibility Requirements
• Confirmed diagnosis
• Physical examination with weight recorded
Study Objective
The National Cancer Institute is looking for Golden Retrievers with Lymphoma, Osteosarcoma, Mast Cell Tumors, and Hemangiosarcoma to participate in a clinical trial
Compensation
If your Golden Retriever is eligible for any of the above mentioned cancer types, the study will pay for full-staging (CBC, Chemistry panel, Urine Analysis, Ultrasound, Radiographs) $800-$1000 of staging. This is not a therapy, chemo or drug study. It is a tissue collection study to populate the tissue bank for future research. After your pets surgery you will be instructed to follow-up with an oncologist or your local veterinarian for follow-up care.
Location of Trial
Davis , CA
More information
Adriamycin vs. Epirubicin Patients with Splenic Hemangiosarcoma
Eligibility Requirements
• Canine patients that have Splenic Hemangiosarcoma and has ruptured with a biopsy to confirm NO liver metastasis
Study Objective
Comparing Adriamycin vs. Epirubicin over the course of six doses.
Compensation
There is no financial incentive. We are currently running studies to compare the use of different drugs in different combinations to provide a more effective way of treating various diseases. Your local veterinarian would call us at UCDavis to 'pull an envelope'. Each envelope is randomly pulled comparing the different drug. There is no placebo and it is 'open-label' meaning you will know exactly what drug your pet is receiving. -top- Please click on the link for more details. .
Location of Trial
Davis, California
More information
Funded Clinical Trial for Splenic Hemangiosarcoma
Eligibility Requirements
• Dogs with confirmed splenic HSA (post-splenectomy)
• Dogs must have a favorable performance status
• NO significant organ dysfunction or concurrent disease(s) that would limit survival
• NO history of kidney disease or proteinuria
• NO prior treatment with high-dose corticosteroids, immunosuppressive agents, chemotherapy, or radiation therapy
• NO vaccination within last four weeks
• Signed informed owner consent; all treatment options for the pet will be presented and owner must decline all other options
• Note: Metastasis is acceptable
Study Objective
Masitinib is a novel oral chemotherapeutic drug (tyrosine kinase inhibitor) that is approved in Europe to treat canine mast cell tumors and also demonstrates in vitro activity against other cancers. The purpose of this prospective, multicenter, phase 2 study is to investigate the safety and anti-cancer activity of masitinib in canine hemangiosarcoma (HSA). In this study, dogs with splenic hemangiosarcoma (post-splenectomy) will be randomly assigned to one of three treatment groups. Group 1: oral masitinib (single agent), Group 2: oral masitinib and doxorubicin combination, Group 3: doxorubicin (single agent). Treatment groups will be compared using biologic parameters, survival time, progression-free interval, and quality of life in dogs with splenic hemangiosarcoma to assess safety and efficacy. .
Compensation
All dogs entering the study will receive chemotherapy (masitinib and/or doxorubicin) in a randomized fashion; no pet will receive a placebo.
The study will partially cover treatment costs associated with the study. Dogs on the masitinib arms will receive free masitinib for the duration of the study. Dogs on the doxorubicin arms will receive $100 toward each doxorubicin treatment, up to five doses.
All other treatment costs, office fees, and all initial and follow up diagnostic charges will be the responsibility of pet owners.
Location of Trial
University of Illinois Cancer Care Clinic
More information
Palladia™ for Canine Splenic Hemangiosarcoma
Eligibility Requirements
• Dogs with histo-confirmed Stage I or II splenic hemangiosarcoma.
• Study enrollment is preceded by successful surgery and 5 doses of doxorubicin chemotherapy, given at 2-week intervals
• Free of metastatic disease 2 weeks after 5th dose of doxorubicin
Study Objective
Canine hemangiosarcoma of the spleen warrants a relatively poor prognosis with only moderate improvements in case outcome with standard chemotherapy. This study will investigate the use of the new receptor tyrosine kinase inhibitor, Palladia™, as a treatment to inhibit metastatic disease after splenectomy and 5 doses of doxorubicin chemotherapy. Treatment will involve giving Toceranib phosphate (Palladia™) orally every other day. Dogs will be rechecked at Weeks 1, 2,and 4 and then monthly thereafter with laboratory work, with complete restaging every 8 weeks.
Compensation
• Free Toceranib phosphate (Palladia™)
• Costs of reassessments (~$2500 to $3000 value) covered once dog is enrolled
Please click on link for more details.
Location of Trial
University of Missouri
More information
Maintenance therapy with toceranib (Palladia) following doxorubicin-based chemotherapy in canine splenic hemangiosarcoma
Eligibility Requirements
• Dog must have histologically confirmed stage I or II (i.e., no evidence of metastasis at the time of diagnosis) splenic HSA
• Must have undergone splenectomy less than than 14 days prior to treatment initiation.
• Must have received 5 doses of single agent doxorubicin following spleen removal (one treatment every 2 weeks)
Study Objective
The purpose of this study is to determine the anti-tumor activity of Palladia against canine hemangiosarcoma.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbus, OH
More information
Metronomic chemotherapy in dogs with splenic hemangiosarcoma
Eligibility Requirements
• Dogs with hemangiosarcoma that have completed a standard course of chemotherapy after removal of the affected spleen.
• Dogs must have a life expectancy of more than 1 month
• Dogs must NOT have lower urinary tract disease
Study Objective
The goal of this study is to evaluate the efficacy of low dose metronomic chemotherapy as a maintenance therapy for dogs with splenic hemangiosarcoma.
Compensation
This study is not funded. Pet owners are responsible for all costs associated with treatment. Please click on link for more details..
Location of Trial
North Grafton, MA
More information
Phase Ib study of GS-424044 in dogs with malignant neoplasia
Eligibility Requirements
• Dogs with advanced solid tumors (mainly carcinomas and sarcomas)
• Dogs with tumor type confirmed by histology (for solid tumors)
• Dogs must weigh at least 10.0kg
• Dogs must be otherwise healthy and at least one year of age.
• Have adequate organ function as specified by standard laboratory tests
Study Objective
The purpose of this study is to investigate a new chemotherapy drug as treatment for dos with malignant tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Athens, GA
More information
Canine patients with osteosarcoma, lymphoma, or oral malignant melanoma, mast cell tumors, soft tissue sarcomas/histiocytic sarcoma/malignant histiocytosis, primary pulmonary cancer, hemangiosarcomas
Eligibility Requirements
• Requirements vary for each type of cancer listed above. Please click on link for more details.
Study Objective
The goal of the CCOGC and UC Davis will be to populate the Pfizer-CCOGC Biospecimen Repository with diseased tissues and specific normal tissues from dogs with cancer over the next three years.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Davis, CA: More information
North Grafton, MA: More information
Madison, WI: More information
Satraplatin for any tumor, including lymphoma
Eligibility Requirements
• Any tumor, including lymphoma confirmed by histopathology or cytology
Study Objective
To determine efficacy of using Satraplatin for various types of cancer using 5mg/m2 daily (orally).
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbia, MO
More information
|
| |
|
